Specialisation
Retina and Vitreous.
Full title
Open-label phase IV trial to examine the change of vision-related quality of life in subjects with diabetic macular oedema (DMO) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.
Promoter
Bayer.
Start date
December 2014.
End date
October 2017.
Researchers
Principal: Dr AnnikenBurés.
